# Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder

> **NCT02414503** · PHASE1,PHASE2 · COMPLETED · sponsor: **OptiNose AS** · enrollment: 17 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** 8IU intranasal oxytocin
- **DRUG:** 24IU intranasal oxytocin
- **DRUG:** Placebo
- **DEVICE:** OptiNose Breath Powered Bi

## Key facts

- **NCT ID:** NCT02414503
- **Lead sponsor:** OptiNose AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2016-09-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414503, "Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02414503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*